Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors

Nat Rev Nephrol. 2017 Dec;13(12):728-730. doi: 10.1038/nrneph.2017.140. Epub 2017 Oct 9.

Authors

Berthold Hocher¹, Oleg Tsuprykov²

Affiliations

¹ Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha 410013, China.
² Institute of Nutritional Science, University of Potsdam, 14558 Nuthetal-Potsdam, Germany.

PMID: 28989173
DOI: 10.1038/nrneph.2017.140

No abstract available

Publication types

News

MeSH terms

Clinical Trials as Topic
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Nephropathies / etiology
Diabetic Nephropathies / prevention & control*
Glucagon-Like Peptide-1 Receptor / agonists*
Humans
Hypoglycemic Agents / therapeutic use*
Liraglutide / therapeutic use*
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Treatment Outcome

Substances

GLP1R protein, human
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Liraglutide